Chlorpromazine eliminates acute myeloid leukemia cells by perturbing subcellular localization of FLT3-ITD and KIT-D816V

[1]  R. Desmorat,et al.  Reduced , 2020, Encyclopedic Dictionary of Archaeology.

[2]  Simon C Watkins,et al.  EGF receptor signaling, phosphorylation, ubiquitylation and endocytosis in tumors in vivo , 2017, eLife.

[3]  C. Zhuo,et al.  Lower risk of liver cancer in patients with schizophrenia: a systematic review and meta-analysis of cohort studies , 2017, Oncotarget.

[4]  C. Bloomfield,et al.  Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation , 2017, The New England journal of medicine.

[5]  R. Larson,et al.  Selective Inhibition of FLT3 by Gilteritinib in Relapsed/Refractory Acute Myeloid Leukemia: a Multicenter, First-in-human, Open-label, Phase 1/2 Study , 2017, The Lancet. Oncology.

[6]  Maria R. Baer,et al.  FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions , 2017, Molecular Cancer Therapeutics.

[7]  M. Levis,et al.  The Future of Targeting FLT3 Activation in AML , 2017, Current Hematologic Malignancy Reports.

[8]  S. Mazhari,et al.  Chlorpromazine versus clotiapine for schizophrenia. , 2017, The Cochrane database of systematic reviews.

[9]  A. Gajra,et al.  Oncotargets and Therapy Dovepress Epidermal Growth Factor Receptor T790m Mutation-positive Metastatic Non-small-cell Lung Cancer: Focus on Osimertinib (azd9291) Epidermal Growth Factor Receptor Mutation (egfrm) and Tyrosine Kinase Inhibitors (tkis) in Non-small-cell Lung Cancer (nsclc) the Incidence , 2022 .

[10]  J. Esteve,et al.  Inhibition of serotonin receptor type 1 in acute myeloid leukemia impairs leukemia stem cell functionality: a promising novel therapeutic target , 2017, Leukemia.

[11]  J. Tamburini,et al.  FLT3 inhibitors: clinical potential in acute myeloid leukemia , 2017, OncoTargets and therapy.

[12]  P. P. Di Fiore,et al.  Endocytic control of signaling at the plasma membrane. , 2016, Current opinion in cell biology.

[13]  R. Garzon,et al.  Acute Myeloid Leukemia: A Concise Review , 2016, Journal of clinical medicine.

[14]  Guillaume Jacquemet,et al.  Endocytic Trafficking of Integrins in Cell Migration , 2015, Current Biology.

[15]  Wen-ying Lee,et al.  Repositioning antipsychotic chlorpromazine for treating colorectal cancer by inhibiting sirtuin 1 , 2015, Oncotarget.

[16]  Sharon E. Miller,et al.  CALM Regulates Clathrin-Coated Vesicle Size and Maturation by Directly Sensing and Driving Membrane Curvature , 2015, Developmental cell.

[17]  H. Esumi,et al.  Oncogenic Kit signals on endolysosomes and endoplasmic reticulum are essential for neoplastic mast cell proliferation , 2014, Nature Communications.

[18]  Itaru Matsumura,et al.  Clathrin Assembly Protein CALM Plays a Critical Role in KIT Signaling by Regulating Its Cellular Transport from Early to Late Endosomes in Hematopoietic Cells , 2014, PloS one.

[19]  C. Man,et al.  FLT3 inhibition: a moving and evolving target in acute myeloid leukaemia , 2013, Leukemia.

[20]  T. Higashi,et al.  Potential use of Folate-appended Methyl-β-Cyclodextrin as an Anticancer Agent , 2013, Scientific Reports.

[21]  Alexander Levitzki,et al.  Tyrosine kinase inhibitors: views of selectivity, sensitivity, and clinical performance. , 2013, Annual review of pharmacology and toxicology.

[22]  Renate Griffith,et al.  Therapeutic targeting of c-KIT in cancer , 2013, Expert opinion on investigational drugs.

[23]  S. Miyamoto,et al.  Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents , 2012, Molecular Psychiatry.

[24]  Johan Lennartsson,et al.  Stem cell factor receptor/c-Kit: from basic science to clinical implications. , 2012, Physiological reviews.

[25]  B. Leber,et al.  Identification of Drugs Including a Dopamine Receptor Antagonist that Selectively Target Cancer Stem Cells , 2012, Cell.

[26]  Andrea I. McClatchey,et al.  Spatial regulation of receptor tyrosine kinases in development and cancer , 2012, Nature Reviews Cancer.

[27]  V. Haucke,et al.  At the Crossroads of Chemistry and Cell Biology: Inhibiting Membrane Traffic by Small Molecules , 2012, Traffic.

[28]  T. Abe,et al.  The Clathrin Assembly Protein PICALM Is Required for Erythroid Maturation and Transferrin Internalization in Mice , 2012, PloS one.

[29]  Sharon E. Miller,et al.  The Molecular Basis for the Endocytosis of Small R-SNAREs by the Clathrin Adaptor CALM , 2011, Cell.

[30]  V. Calléja,et al.  A direct role for Met endocytosis in tumorigenesis , 2011, Nature Cell Biology.

[31]  M. Minden,et al.  A phase I/II study of imatinib plus reinduction therapy for c-kit-positive relapsed/refractory acute myeloid leukemia: inhibition of Akt activation correlates with complete response , 2011, Leukemia.

[32]  S. Gygi,et al.  Multiple mechanisms collectively regulate clathrin-mediated endocytosis of the epidermal growth factor receptor , 2010, The Journal of cell biology.

[33]  R. Vandenbroucke,et al.  Title: the Use of Inhibitors to Study Endocytic Pathways of Gene Carriers: Optimisation and Pitfalls the Use of Inhibitors to Study Endocytic Pathways of Gene Carriers: Optimisation and Pitfalls Dries Vercauteren , 2022 .

[34]  M. Mann,et al.  Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes. , 2009, Molecular cell.

[35]  D. Schmidt-Arras,et al.  Anchoring of FLT3 in the endoplasmic reticulum alters signaling quality. , 2009, Blood.

[36]  P. Aplan,et al.  The role of CALM–AF10 gene fusion in acute leukemia , 2008, Leukemia.

[37]  T. Ban.  Fifty years chlorpromazine: a historical perspective , 2007, Neuropsychiatric disease and treatment.

[38]  W. Hiddemann,et al.  Acute myeloid leukemia is propagated by a leukemic stem cell with lymphoid characteristics in a mouse model of CALM/AF10-positive leukemia. , 2006, Cancer cell.

[39]  K. Sakamoto,et al.  FMS‐Like Tyrosine Kinase 3 in Normal Hematopoiesis and Acute Myeloid Leukemia , 2006, Stem cells.

[40]  A. Achiron,et al.  Reduced cancer incidence among patients with schizophrenia , 2005, Cancer.

[41]  P. Seeman.  An update of fast-off dopamine D2 atypical antipsychotics. , 2005, The American journal of psychiatry.

[42]  T. Brümmendorf,et al.  Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. , 2004, Blood.

[43]  A. Marx,et al.  Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia. , 2004, Blood.

[44]  Y. Shinohara,et al.  Phenothiazines suppress proliferation and induce apoptosis in cultured leukemic cells without any influence on the viability of normal lymphocytes , 2004, Cancer Chemotherapy and Pharmacology.

[45]  Mitchell L. Klebig,et al.  Mutations in the clathrin-assembly gene Picalm are responsible for the hematopoietic and iron metabolism abnormalities in fit1 mice , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[46]  J. Schlessinger,et al.  Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.

[47]  V. Godfrey,et al.  Mutations in the murine fitness 1 gene result in defective hematopoiesis. , 1997, Blood.

[48]  J. Rowley,et al.  The t(10;11)(p13;q14) in the U937 cell line results in the fusion of the AF10 gene and CALM, encoding a new member of the AP-3 clathrin assembly protein family. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[49]  Preben Bo Mortensen,et al.  The occurence of cancer in first admitted schizophrenic patients , 1994, Schizophrenia Research.

[50]  T. Farrah,et al.  Molecular cloning of a ligand for the flt3 flk-2 tyrosine kinase receptor: A proliferative factor for primitive hematopoietic cells , 1993, Cell.

[51]  S. Nishikawa,et al.  Expression and function of c-kit in hemopoietic progenitor cells , 1991, The Journal of experimental medicine.

[52]  H. Meltzer,et al.  Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. , 1989, The Journal of pharmacology and experimental therapeutics.

[53]  P. Mortensen,et al.  The incidence of cancer in schizophrenic patients. , 1989, Journal of epidemiology and community health.

[54]  N. C. Rassidakis,et al.  On the incidence of malignancy among schizophrenic patients. , 1973, Agressologie: revue internationale de physio-biologie et de pharmacologie appliquees aux effets de l'agression.

[55]  L. Csatary.  Chlorpromazines and cancer. , 1972, Lancet.

[56]  S. Snyder,et al.  Chlorpromazine and dopamine: conformational similarities that correlate with the antischizophrenic activity of phenothiazine drugs. , 1971, Proceedings of the National Academy of Sciences of the United States of America.

[57]  R. Patton,et al.  Cancer mortality among patients in New York mental hospitals , 1967, Cancer.

[58]  A. Gajra,et al.  Epidermal growth factor receptor T790M mutation-positive metastatic non-small-cell lung cancer: focus on osimertinib (AZD9291) , 2017, OncoTargets and therapy.

[59]  J. Tamburini,et al.  FLT 3 inhibitors : clinical potential in acute myeloid leukemia , 2017 .

[60]  Stuart Moss,et al.  Current Status and Future Directions , 2013 .

[61]  Bert R. Mandelbaum,et al.  From Basic Science to Clinical Applications , 2009 .

[62]  M. Talpaz,et al.  CHRONIC MYELOID LEUKEMIA: AFTER A DECADE OF IMATINIB _________________________________________________________ , 2022 .

[63]  Jeremy Fairbank,et al.  Historical Perspective , 1987, Do We Really Understand Quantum Mechanics?.

[64]  J. Schlessinger,et al.  Signaling by Receptor Tyrosine Kinases , 1993 .